

# Single-nucleotide polymorphisms of microRNA processing machinery genes and risk of colorectal cancer

Yufei Zhao  
Yanming Du  
Shengnan Zhao  
Zhanjun Guo

Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China

**Objective:** MicroRNA (miRNA)-related single-nucleotide polymorphisms (miR-SNPs) in miRNA processing machinery genes can affect cancer risk, treatment efficacy, and patient prognosis. We genotyped 6 miR-SNPs of miRNA processing machinery genes including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348) in a case-control study to evaluate their impact on colorectal cancer (CRC) risk.

**Materials and methods:** miR-SNPs were genotyped using the polymerase chain reaction–ligase detection reaction. The  $\chi^2$  test was used to analyze dichotomous values, such as the presence or absence of any individual SNP in CRC patients and healthy controls.

**Results:** Two of these SNPs were identified for their association with cancer risk in the *Dicer* and *GEMIN3* genes. The AA allele of rs3742330 located in the *Dicer* gene exhibited a significantly increased risk of CRC (odds ratio, 2.11; 95% confidence interval: 1.33–3.34;  $P=0.001$ ); the TT allele of rs197412 located in *GEMIN3* also exhibited a significantly increased risk of CRC (odds ratio, 1.68; 95% confidence interval: 1.07–2.65;  $P=0.024$ ).

**Conclusion:** Our results suggest that the specific genetic variants in miRNA machinery genes may affect CRC susceptibility.

**Keywords:** miR-SNP, CRC, *GEMIN3*, *Dicer*

## Introduction

Colorectal cancer (CRC) is the third most common cancer in males and the second in females, which make it the third most common cause of cancer-related mortality in both sexes worldwide.<sup>1</sup> It accounts for an estimated 1.2 million new cancer cases and over 630,000 cancer deaths per year.<sup>2</sup> The CRC incidence displayed a trend of rapid rise in a study involving Asian countries including the People's Republic of China, Japan, South Korea, and Singapore.<sup>3</sup> Dietary patterns, obesity, smoking, heavy alcohol consumption, physical inactivity, genetic and epigenetic have been identified as risk factors for CRC,<sup>4–6</sup> but the underlying mechanism of this cancer remains unknown.<sup>7–10</sup>

MicroRNAs (miRNAs) are RNA molecules that are ~22 nucleotides long and which play important roles in various biological processes, such as embryonic development, cell differentiation, proliferation, apoptosis, cancer development, and insulin secretion.<sup>11,12</sup> A growing body of studies suggests that miRNAs play important roles in cancer development through regulating the expressions of proto-oncogenes or tumor suppressor genes.<sup>11,13,14</sup> During miRNA processing, long primary transcripts of miRNAs (pri-miRNAs) are processed in the nucleus by the RNase III Droscha and are transported to the cytoplasm by the nuclear transport factor exportin-5 (*XPO5*) and *RAN*. In the cytoplasm, RNase III *Dicer* and transactivation-responsive RNA-binding

Correspondence: Zhanjun Guo  
Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang 050011, People's Republic of China  
Tel +86 311 8609 5342  
Fax +86 311 8383 2916  
Email zjguo5886@aliyun.com

protein (TRBP) mediate pre-miRNA processing to release a 21-bp miRNA, the RNA-induced silencing complex (RISC) including *GEMIN3* and *GEMIN4* will select one strand as the mature miRNA and guide mature miRNAs to their target mRNA sites.<sup>11,15-19</sup> miRNA-related single-nucleotide polymorphisms (miR-SNPs), defined as single-nucleotide polymorphisms (SNPs) in miRNA genes, miRNA binding site and miRNA processing machinery, are able to modulate miRNA and target gene expressions so as to influence cancer risk, treatment efficacy, and patient prognosis.<sup>19-22</sup>

It is reported that genetic variants in both miRNA processing pathway genes and miRNA genes might affect susceptibility to cancers such as bladder cancer, esophageal cancer, and renal cell carcinoma, but few studies focus on miR-SNPs of miRNA processing machinery genes and CRC risk.<sup>23-25</sup> In the present study, we genotyped six miR-SNPs of miRNA processing machinery genes including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348), which have shown susceptibility to carcinogenesis in a previous report, in a case-control study to evaluate the impact of these miR-SNPs on CRC risk.<sup>19</sup>

## Materials and methods

### Tissue specimens and DNA extraction

Blood samples were collected at the Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China from 163 CRC patients who underwent tumor resection in the Department of Surgery. Blood samples were also collected from 142 age- and sex-matched health controls.

The personal information about smoking, obesity, and alcohol consumption were reviewed in patients and controls. Total DNA was extracted using the Wizard Genomic DNA extraction kit (Promega Corporation, Fitchburg, WI, USA) and stored at -20°C. The program was approved by the Human Tissue Research Committee of the Fourth Hospital of Hebei Medical University. Written informed consent was obtained from all the patients for the collection of samples and subsequent analysis.

### Genotyping of miR-SNPs

The miR-SNPs of the miRNA processing genes including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348) were genotyped with polymerase chain reaction-ligase detection reaction assay that amplify the DNA fragment flanking miR-SNPs basing on the sequence in the NCBI SNP database (<http://www.ncbi.nlm.nih.gov/snp/>). All the primers and probes are listed in Table 1. The ligation was performed using the different probes matched to the miR-SNPs, and the ligated products were separated using the ABI PRISM Genetic Analyzer 3730XL (Thermo Fisher Scientific, Waltham, MA, USA). Polymorphisms were confirmed based on the length difference of ligated products.

### Measurement of *Dicer* levels in CRC tissue

*Dicer* immunochemistry was performed with CRC tissue. The tissue sections were incubated with an anti-*Dicer* antibody (Abcam, Cambridge, UK) at a dilution of 1:100 overnight

**Table 1** Primers and probes used for genotyping of miR-SNPs

| Gene          | rs NCBI         | Primer sequence                                      | Probe sequence  |
|---------------|-----------------|--|---|
| <i>XPO5</i>   | rs11077 (A/C)   | F GAATCTGGTCACTGATGGGA<br>R GTGCCTGAGTGACCTTGAG      | S1 GTACCTCCAAGGACCAGGGCTGGGA<br>S2 TTTGTACCTCCAAGGACCAGGGCTGGGC<br>S3 AGTCTTTAGTGCTAACATCCCCTTT                   |
| <i>RAN</i>    | rs14035 (C/T)   | F GCACTTGCTCAAAATCTGTGA<br>R TAACAGCAAGAATTCCCAACC   | S1 TTTTAGTAATCATGTTTTAATGTAGAACC<br>S2 TTTTTTTAGTAATCATGTTTTAATGTAGAACC<br>S3 TCAAACAGGATGGAACATCAGTGGATTT        |
| <i>Dicer1</i> | rs3742330 (A/G) | F AAAGGTATCAAGGTCTCAGTTTG<br>R CTGCAGAGGATCACTGGAATC | S1 TTTTTTTTTCAATCTTGTTAAAGGGATTAGA<br>S2 TTTTTTTTTTTTCAATCTTGTTAAAGGGATTAGG<br>S3 CACCCTAACAGAGCAAGATCCAATATTTTTT |
| <i>TNRC6B</i> | rs9623117 (C/T) | F TTTCTGTCTCCTCTATCCAT<br>R CATTAGTTTAGCCAACAAGGT    | S1 TCTCCCTGTTACTCTTAAGTAGTGC<br>S2 TTTTCTCCCTGTTACTCTTAAGTAGTGT<br>S3 CTCCTTTCCCATCCACCCCATCTC                    |
| <i>GEMIN3</i> | rs197412 (T/C)  | F TAGAGAACTGTGGAATCA<br>R GAAGAGGTTCTTGAGCTGTAA      | S1 TTTTATGGTTTTGTGAGAAATAAAGTTAC<br>S2 TTTTTTTATGGTTTTGTGAGAAATAAAGTTAT<br>S3 TGAACAGAGAGTCCCTGTGTTGGCATT         |
| <i>GEMIN4</i> | rs2740348 (G/C) | F TTGCCTCTGAGAAGAAGTGG<br>R GACTCAGGGATGGCTCTGTC     | S1 TTTTTTTGGGAGTAACAGGGCCCTCTCCGAC<br>S2 TTTTTTTTTTTGGGAGTAACAGGGCCCTCTCCGAG<br>S3 AGCCAGACTTGGTGTGAGGCTGCTTTTTTT |

**Abbreviation:** miR-SNPs, microRNA-related single-nucleotide polymorphisms.

at 4°C followed by incubation with a biotinylated secondary anti-rabbit IgG antibody for 1 hour at room temperature. The sections were subsequently incubated with HRP-conjugated streptavidin and developed using 3,3-diaminobenzidine.

The immunostaining results for all receptors were semi-quantified by two investigators using the HSCORE as described previously.<sup>26</sup> Briefly, the score was calculated by the percentage of positively stained CRC tissue with five intensity categories (0, 1+, 2+, 3+, and 4+). The HSCORE represents the sum of each of the percentages multiplied by the weighted intensity of staining as follows:

$$\text{HSCORE} = (i+1) \pi, \quad (1)$$

where  $i=1, 2, 3,$  and  $4$  and  $\pi$  varies from 0% to 100% for the percentage of positive stained area. A score  $>100\%$  was defined as high expression and  $\leq 100\%$  as low expression

## Statistical analysis

The  $\chi^2$  test was used to analyze dichotomous values, such as the presence or absence of any individual SNP in CRC patients and healthy controls. Statistical analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). For all the statistical tests,  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

A total of 163 CRC patients were enrolled in this study. The control group consisted of 142 people without any history of hereditary or malignant disease by physical and imaging examinations. No distribution difference existed between patients and controls referring to age and sex. All patients and controls were the same nationality (Han Chinese) and recruited from Shijiazhuang and surrounding areas in North China. The clinical characteristics of the CRC patients and healthy controls are listed in Table 2.

We genotyped the six miR-SNPs of miRNA processing machinery genes including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348) in 163 CRC patients and 142 healthy controls and evaluated the impact of these miR-SNPs on CRC risk. The genotype distributions and allele frequencies of the SNPs are shown in Table 3. Two SNPs of these miR-SNPs were identified for their association with CRC risk by  $\chi^2$  test. For the rs3742330 located in *Dicer* genes, the frequencies of genotype AA and AG + GG were 56.4% and 43.6% in patients but 38.0% and 62.0% in the controls. The AA genotype carrier of rs3742330 was associated with a 2.11-fold increased risk when compared with AG + GG

**Table 2** Association of clinical characteristics with cancer risk in CRC patients

|                     | CRC (n=163) | Control (n=142) | P-value |
|---------------------|-------------|-----------------|---------|
| Age (years)         |             |                 |         |
| $\leq 60$           | 79          | 66              |         |
| $> 60$              | 84          | 76              | 0.729   |
| Sex                 |             |                 |         |
| Male                | 93          | 93              |         |
| Female              | 70          | 49              | 0.132   |
| Smoking             |             |                 |         |
| Yes                 | 32          | 36              |         |
| No                  | 131         | 106             | 0.231   |
| Obesity             |             |                 |         |
| Yes                 | 12          | 18              |         |
| No                  | 151         | 124             | 0.120   |
| Alcohol consumption |             |                 |         |
| Yes                 | 27          | 30              |         |
| No                  | 136         | 112             | 0.308   |
| Tumor stage, TNM    |             |                 |         |
| I                   | 9           |                 |         |
| II                  | 82          |                 |         |
| III                 | 53          |                 |         |
| IV                  | 19          |                 |         |

**Abbreviation:** CRC, colorectal cancer.

genotype carrier (odds ratio, 2.11; 95% confidence interval: 1.33–3.34;  $P=0.001$ ). As for the rs197412 located in *GEMIN3*, the frequencies of genotype TT and CT + CC were 55.2% and 44.8% in the patients and 42.3% and 57.7% in controls. The TT genotype carrier showed a significantly increased risk for CRC compared with CT + CC carrier (odds ratio, 1.68; 95% confidence interval: 1.07–2.65;  $P=0.024$ ).

One hundred and sixty-four CRC patients including 89 rs3742330 AA carriers and 75 rs3742330 AG + GG carriers with cancer tissue available were used for *Dicer* protein measurement by immunostaining. The AA type (35 high *Dicer* expression and 54 low *Dicer* expression) displayed a great trend toward association with low *Dicer* expression at borderline statistical level ( $P=0.073$ ) compared with that of AG + GG (40 high *Dicer* expression and 35 low *Dicer* expression).

## Discussion

The identification of predictive markers from miR-SNPs for cancer risk is a new field in cancer research. We evaluated the potential associations of six miR-SNPs in miRNA processing machinery genes including *XPO5* (rs11077), *RAN* (rs14035), *Dicer* (rs3742330), *TNRC6B* (rs9623117), *GEMIN3* (rs197412), and *GEMIN4* (rs2740348) with the risk of CRC. Two miR-SNPs in *Dicer* (rs3742330) and *GEMIN3* (rs197412) were found to be associated with CRC risk.

*Dicer* is an endonuclease in the RNase III family that specially cleaves double-stranded RNAs to produce miRNA and

**Table 3** Associations of the six SNPs with colorectal cancer risk

| Gene          | SNP       | Genotype | Number (%) of patients with each genotype |            | Odds ratio | 95% CI    | P-value |
|---------------|-----------|----------|---|------------|------------|-----------|---------|
|               |           |          | Case                                      | Control    |            |           |         |
| XPO5          | rs11077   | AA       | 143 (12.3)                                | 123 (86.6) | 1.10       | 0.56–2.16 | 0.772   |
|               |           | AC + CC  | 20 (87.7)                                 | 19 (13.4)  |            |           |         |
| RAN           | rs14035   | CC       | 113 (69.3)                                | 107 (75.4) | 0.74       | 0.45–1.23 | 0.242   |
|               |           | CT + TT  | 50 (30.7)                                 | 35 (24.6)  |            |           |         |
| <i>Dicer</i>  | rs3742330 | AA       | 92 (56.4)                                 | 54 (38.0)  | 2.11       | 1.33–3.34 | 0.001   |
|               |           | AG + GG  | 71 (43.6)                                 | 88 (62.0)  |            |           |         |
| <i>TNRC6B</i> | rs9623117 | TT       | 149 (91.4)                                | 128 (90.1) | 1.16       | 0.54–2.53 | 0.702   |
|               |           | CT + CC  | 14 (8.6)                                  | 14 (9.9)   |            |           |         |
| <i>GEMIN3</i> | rs197412  | TT       | 90 (55.2)                                 | 60 (42.3)  | 1.69       | 1.07–2.65 | 0.024   |
|               |           | CT + CC  | 73 (44.8)                                 | 82 (57.7)  |            |           |         |
| <i>GEMIN4</i> | rs2740348 | GG       | 128 (78.5)                                | 114 (80.3) | 0.89       | 0.51–1.57 | 0.706   |
|               |           | GC + CC  | 35 (21.5)                                 | 28 (19.7)  |            |           |         |

**Abbreviations:** CI, confidence interval; SNP, single-nucleotide polymorphism.

small interfering RNA so as to repress gene expression.<sup>27,28</sup> The miR-SNP of rs3742330 of *Dicer* has been identified for its association with the cancer outcome of T-cell lymphoma as well as the risk of oral premalignant lesions and renal cell carcinoma.<sup>25,29,30</sup> The mechanism by which this SNP modifies the CRC risk remains unclear. rs3742330 located in the 3'-untranslated region of *Dicer* might potentially influence the gene stability and expression. Our immunostaining data show that this SNP seems to associate with different *Dicer* expression levels. Moreover, the altered *Dicer* expression may further affect miRNA expression profiles, thereby mediates the CRC carcinogenesis, deregulation of *Dicer* are strongly associated with the adverse development of CRC.<sup>31</sup>

GEMIN proteins in miRNA ribonucleoprotein particles is involved in the processing of miRNA precursors through their interaction with the key components of the RNA-induced silencing complex.<sup>25,32,33</sup> rs197412 located in exon 11 of *GEMIN3* gene could induce Ile to Thr substitution at 636 amino acid position through the T to C transition. This SNP showed a trend toward susceptibility to the risk of renal cell carcinoma.<sup>25</sup> This amino acid substitution might change mRNA stability or protein function, thereby influencing miRNA expression profiles to modify the CRC carcinogenesis. In addition, *GEMIN3* can form a complex with p53 and EBNA3C through the C-terminal domain (amino acid 546-825) to block p53-mediated apoptosis.<sup>34</sup> The amino acid substitution of this miR-SNP, which is located in the C-terminal of *GEMIN3*, might alter binding affinity to p53, thereby modifying the apoptosis process of CRC cells.

The relationships of the frequency distribution of these two SNPs and metastasis status were compared; no association exists by our analysis (data not shown). These six miR-SNPs

were analyzed for their association with postoperative survival in 55 patients with 5-year follow-up data available. rs14035 and rs3742330 showed association with survival at borderline statistical level (Fan et al, unpublished data, 2014), these findings should be validated in a larger sample size.

To our knowledge, this is the first study investigating the associations between SNPs of miRNA processing machinery genes and CRC susceptibility. miR-SNPs emerged as new promising markers for disease prediction in cancer. Although miR-SNP studies for miRNA processing machinery genes are at an early stage, our results are encouraging because they indicate that miR-SNPs may have an effect on cancer susceptibility. However, further laboratory-based functional studies in other populations are warranted to validate these results.

## Acknowledgment

This work was supported by the Key Basic Research Program of Hebei (14967713D).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
- Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*. 2006;24(14):2137–2150.
- Sung JJ, Lau JY, Goh KL, Leung WK; Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. *Lancet Oncol*. 2005;6(11):871–876.
- Bishehsari FJ. *B. Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management*. United States: Demos Medical Publishing, Inc; 2013.

5. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT; Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. *Lancet*. 2012;380(9838):219–229.
6. Zoratto F, Rossi L, Verrico M, et al. Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. *Tumor Biol*. 2014;35(7):6195–6206.
7. Landi D, Gemignani F, Naccarati A, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. *Carcinogenesis*. 2008;29(3):579–584.
8. Landi D, Gemignani F, Pardini B, et al. Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. *Cancer*. 2012;118(19):4670–4680.
9. Azimzadeh P, Romani S, Mohebbi SR, et al. Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population. *Cancer Genet*. 2012;205(10):501–507.
10. Pan XM, Sun RF, Li ZH, et al. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. *Tumour Biol*. 2014;35(1):831–835.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004;116(2):281–297.
12. Ambros V. The functions of animal microRNAs. *Nature*. 2004;431(7006):350–355.
13. Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. *Nat Rev Cancer*. 2006;6(4):259–269.
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. *Nat Rev Cancer*. 2006;6(11):857–866.
15. Cullen BR. Transcription and processing of human microRNA precursors. *Mol Cell*. 2004;16(6):861–865.
16. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature*. 2003;425(6956):415–419.
17. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev*. 2003;17(24):3011–3016.
18. Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature*. 2005;436(7051):740–744.
19. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. *Nat Rev Cancer*. 2010;10(6):389–402.
20. Campayo M, Navarro A, Viñolas N, et al. A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma. *PLoS One*. 2011;6(7):e22509.
21. de Larrea CF, Navarro A, Tejero R, et al. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. *Clin Cancer Res*. 2012;18(13):3697–3704.
22. Boni V, Zarate R, Villa JC, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. *Pharmacogenomics J*. 2011;11(6):429–436.
23. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. *Cancer Res*. 2008;68(7):2530–2537.
24. Ye Y, Wang KK, Gu J, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. *Cancer Prev Res (Phila)*. 2008;1(6):460–469.
25. Horikawa Y, Wood CG, Yang H, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. *Clin Cancer Res*. 2008;14(23):7956–7962.
26. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. *N Engl J Med*. 2008;359:2641–2650.
27. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature*. 2001;409(6818):363–366.
28. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet*. 2002;3(10):737–747.
29. Li X, Tian X, Zhang B, Zhang Y, Chen J. Variation in dicer gene is associated with increased survival in T-cell lymphoma. *PLoS One*. 2012;7(12):e51640.
30. Clague J, Lippman SM, Yang H, et al. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. *Mol Carcinog*. 2010;49(2):183–189.
31. Faggad A, Kasajima A, Weichert W, et al. Down-regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. *Histopathology*. 2012;61(4):552–561.
32. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. *Science*. 2002;297(5589):2056–2060.
33. Dostie J, Mourelatos Z, Yang M, Sharma A, Dreyfuss G. Numerous microRNPs in neuronal cells containing novel microRNAs. *RNA*. 2003;9(2):180–186.
34. Cai Q, Guo Y, Xiao B, et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. *PLoS Pathog*. 2011;7(12):e1002418.

## OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress